Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + 5-fluorouracil + cisplatin
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Toripalimab is a humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, developed by Shanghai Junshi Biosciences. In a clinical trial context led by Ruijin Hospital, it is being investigated as an induction therapy in combination with a chemotherapy regimen consisting of 5-fluorouracil and cisplatin (or carboplatin) for patients with locoregionally-advanced laryngo-hypopharyngeal squamous cell carcinoma. The mechanism of action involves toripalimab blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2) to restore anti-tumor T-cell activity, while the chemotherapy components provide cytotoxic effects by inhibiting DNA synthesis and inducing DNA damage. This combination approach is intended to reduce tumor burden and improve organ preservation rates in patients with locally advanced laryngeal and hypopharyngeal cancers.
- Brand names
- LoqtorziTuoyi
- Other names
- toripalimab-Ruijin Hospital-laryngo-hypopharyngeal squamous cell carcinomatoripalimab-tpgnFP combined with Toripalimab
02
Targets
TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on toripalimab + 5-fluorouracil + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + 5-fluorouracil + cisplatin.